1.A single-center, retrospective analysis of relapse and progression patterns of primary central nervous system lymphoma: can whole brain radiotherapy be replaced?.
Yue QIN ; Rongping LIU ; Xiaonan ZHANG ; Wan ZHANG ; Chen REN ; Dehua WU
Journal of Southern Medical University 2023;43(4):499-506
OBJECTIVE:
To analyze recurrence and progression patterns of primary central nervous system lymphoma (PCNSL) in patients without whole brain radiotherapy (WBRT) and assess the value of WBRT in PCNSL treatment.
METHODS:
This retrospective single-center study included 27 patients with PCNSL, who experienced recurrence/progression after achieving complete remission (CR), partial remission, or stable disease following initial treatments with chemotherapy but without WBRT. The patients were followed up regularly after the treatment for treatment efficacy assessment. By comparing the anatomical location of the lesions on magnetic resonance images (MRI) at the initial diagnosis and at recurrence/progression, we analyzed the patterns of relapse/progression in patients with different treatment responses and different initial status of the lesions.
RESULTS:
MRI data showed that in 16 (59.26%) of the 27 patients, recurrence/progression occurred in out-field area (outside the simulated clinical target volume [CTV]) but within the simulated WBRT target area in 16 (59.26%) patients, and within the CTV (in-field) in 11 (40.74%) patients. None of the patients had extracranial recurrence of the tumor. Of the 11 patients who achieved CR after the initial treatments, 9 (81.82%) had PCNSL recurrences in the out-field area but within WBRT target area; of the 13 patients with a single lesion at the initial treatment, 11 (84.62%) experienced PCNSL recurrence in the out-field area but within WBRT target area.
CONCLUSIONS
Systemic therapy combined with WBRT still remains the standard treatment for PCNSL patients, especially those who achieve CR after treatment or have a single initial lesion. Future prospective studies with larger sample sizes are needed to further explore the role of low-dose WBRT in PCNSL treatment.
Humans
;
Lymphoma/radiotherapy*
;
Central Nervous System Neoplasms/pathology*
;
Retrospective Studies
;
Prospective Studies
;
Neoplasm Recurrence, Local/drug therapy*
;
Combined Modality Therapy
;
Brain/pathology*
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
;
Methotrexate
2.Radiotherapy targeting cancer stem cells "awakens" them to induce tumour relapse and metastasis in oral cancer.
Yangfan LIU ; Miao YANG ; Jingjing LUO ; Hongmei ZHOU
International Journal of Oral Science 2020;12(1):19-19
Radiotherapy is one of the most common treatments for oral cancer. However, in the clinic, recurrence and metastasis of oral cancer occur after radiotherapy, and the underlying mechanism remains unclear. Cancer stem cells (CSCs), considered the "seeds" of cancer, have been confirmed to be in a quiescent state in most established tumours, with their innate radioresistance helping them survive more easily when exposed to radiation than differentiated cancer cells. There is increasing evidence that CSCs play an important role in recurrence and metastasis post-radiotherapy in many cancers. However, little is known about how oral CSCs cause tumour recurrence and metastasis post-radiotherapy. In this review article, we will first summarise methods for the identification of oral CSCs and then focus on the characteristics of a CSC subpopulation induced by radiation, hereafter referred to as "awakened" CSCs, to highlight their response to radiotherapy and potential role in tumour recurrence and metastasis post-radiotherapy as well as potential therapeutics targeting CSCs. In addition, we explore potential therapeutic strategies targeting these "awakened" CSCs to solve the serious clinical challenges of recurrence and metastasis in oral cancer after radiotherapy.
Humans
;
Mouth Neoplasms
;
pathology
;
radiotherapy
;
Neoplasm Recurrence, Local
;
radiotherapy
;
Neoplastic Stem Cells
;
pathology
;
radiation effects
;
Radiotherapy
;
methods
;
Recurrence
3.Treatment and outcome of recurrent cervical lymph nodes in patients with nasopharyngeal carcinoma after radiotherapy.
Yongli WANG ; Guiping LAN ; Yongfeng SI ; Zhuoxia DENG ; Jinjie SUN ; Yong YANG ; Xing HAN ; Jingjin WENG ; Fuling ZHOU
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2016;51(3):183-188
OBJECTIVETo evaluate the efficacies of different treatments for recurrent cervical lymph nodes and the factors contributing to prognosis in patients with nasopharyngeal carcinoma after radiotherapy.
METHODSClinical data of 79 patients with nasopharyngeal carcinoma after radiotherapy were retrospectively analyzed, and all cases were diagnosed as having recurrent cervical lymph nodes by pathological examination. The factors including sex, age, the interval between completion of radiotherapy and recurrence, rN stage, treatment methods, and the location relationship between recurrent lesion and primary tumor in the neck were analyzed for prognosis. Kaplan-Meier curves, Log-rank test and Cox's proportional hazards regression mode were used in the statistical analysis.
RESULTSThe median recurrence time was 26 months, and the 1- , 3- and 5-year overall survival rates were 77.9%, 53.4% and 39.7%. Cox's proportional hazards regression mode analysis indicated that age, rN stage, treatment methods, and the location relationship between recurrent lesion and primary tumor were significantly prognostic factors.
CONCLUSIONSNeck dissection is superior to re-radiotherapy in treatment of recurrent cervical lymph nodes in nasopharyngeal carcinoma after radiotherapy. The patients younger than 45 years old, in early rN stage and for recurrence in the center region of primary tumor have a better prognosis.
Carcinoma ; Humans ; Kaplan-Meier Estimate ; Lymph Nodes ; pathology ; Nasopharyngeal Neoplasms ; radiotherapy ; Neck ; Neck Dissection ; Neoplasm Recurrence, Local ; surgery ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Survival Rate ; Treatment Outcome
4.Carcinoma of the cervix in elderly patients treated with radiotherapy: patterns of care and treatment outcomes.
Ming Yin LIN ; Srinivas KONDALSAMY-CHENNAKESAVAN ; David BERNSHAW ; Pearly KHAW ; Kailash NARAYAN
Journal of Gynecologic Oncology 2016;27(6):e59-
OBJECTIVE: The aim of this analysis was to examine the management of cervix cancer in elderly patients referred for radiotherapy and the results of treatment in terms of overall survival (OS), relapse-free survival (RFS), and treatment-related toxicities. METHODS: Patients were eligible if they were aged ≥75 years, newly diagnosed with cervix cancer and referred for radiotherapy as part of their treatment. Patient details were retrieved from the gynaecology service database where clinical, histopathological treatment and follow-up data were prospectively collected. RESULTS: From 1998 to 2010, 126 patients aged ≥75 years, met selection criteria. Median age was 81.5 years. Eighty-one patients had definitive radiotherapy, 10 received adjuvant radiotherapy and 35 had palliative radiotherapy. Seventy-one percent of patients had the International Federation of Gynecology and Obstetrics stage 1b–2b disease. Median follow-up was 37 months. OS and RFS at 3 years among those treated with curative intent were 66.6% and 75.9% respectively with majority of patients dying without any evidence of cervix cancer. Grade 2 or more late toxicities were: bladder 5%, bowel 11%, and vagina 27%. Eastern Cooperative Oncology Group (ECOG) status was a significant predictor of OS and RFS with each unit increment in ECOG score increased the risk of death by 1.69 times (p<0.001). CONCLUSION: Following appropriate patient selection, elderly patients treated curatively with radiotherapy for cervix cancer have good disease control. Palliative hypofractionated regimens are well tolerated in patients unsuitable for radical treatment.
Aged
;
Aged, 80 and over
;
Brachytherapy
;
Female
;
Humans
;
Lymphatic Metastasis
;
Neoplasm Recurrence, Local/prevention & control
;
Neoplasm Staging
;
Palliative Care
;
Radiotherapy, Adjuvant/adverse effects
;
Survival Rate
;
*Treatment Outcome
;
Uterine Cervical Neoplasms/mortality/pathology/*radiotherapy
5.Details of recurrence sites after definitive radiation therapy for cervical cancer.
Reiko KOBAYASHI ; Hideomi YAMASHITA ; Kae OKUMA ; Kuni OHTOMO ; Keiichi NAKAGAWA
Journal of Gynecologic Oncology 2016;27(2):e16-
OBJECTIVE: This is a retrospective study aimed at clarifying the details of recurrence patterns and sites in patients with cervical cancer treated with definitive radiation therapy (RT). METHODS: Data were analyzed from consecutive patients, admitted to the University of Tokyo Hospital (Tokyo, Japan) between 2001 and 2013, who had received definitive RT, with or without chemotherapy, for International Federation of Gynecology and Obstetrics stages IB-IVA cervical cancer. RESULTS: One hundred and thirty-seven patients formed the patient cohort. The median follow-up period for surviving patients was 57.0 months. A complete response was achieved in 121 patients (88%). Of these, 36 (30%) developed a cancer recurrence during follow-up. The first sites of recurrence were located in intra-RT fields in nine, outside RT fields in 20, and both in seven patients. In the intra-RT field group, all patients showed a local recurrence, while no one experienced an isolated pelvic lymph node (PLN) recurrence. In the outside RT field group, the most frequent site of recurrence was lung (60%), and three-quarters of patients were free from intra-RT field recurrence until the last follow-up. Of the entire cohort, including 48 PLN-positive patients, only seven patients (5.1%) developed PLN persistence or recurrence, all in the common iliac, internal iliac, and/or obturator nodes, and all with another synchronous relapse. CONCLUSION: Local disease was a major type of intra-RT field recurrence, while PLN control was favorable even in initially PLN-positive patients. The predominance of outside RT field recurrence alone highlights issues concerning distant control, including the intensity enhancement of systematic therapy.
Adenocarcinoma/drug therapy/*radiotherapy/secondary
;
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Agents/therapeutic use
;
Brachytherapy
;
Carcinoma, Squamous Cell/drug therapy/*radiotherapy/secondary
;
Chemoradiotherapy
;
Disease-Free Survival
;
Dose Fractionation
;
Female
;
Follow-Up Studies
;
Humans
;
Lung Neoplasms/*secondary
;
Lymphatic Metastasis
;
Middle Aged
;
Neoplasm Recurrence, Local/*diagnosis
;
Pelvis
;
Retrospective Studies
;
Survival Rate
;
Uterine Cervical Neoplasms/drug therapy/pathology/*radiotherapy
6.Synchronous and metachronous malignancy in endometrial cancer patients treated in a tertiary care center of Thailand.
Siriwan TANGJITGAMOL ; Jakkapan KHUNNARONG ; Sunamchok SRIJAIPRACHAROEN
Journal of Gynecologic Oncology 2015;26(4):293-302
OBJECTIVE: To evaluate the prevalence and features of non-endometrial cancers in Thai endometrial cancer (EC) patients. METHODS: EC patients treated in our institution were identified and the following data were collected: age, EC stage, histopathology, adjuvant therapy, other cancers, living status, and cause of death. RESULTS: The mean age of the 344 patients was 56.8+/-10.8 years. Fifty (14.5%) had other synchronous and metachronous cancers. Mean ages of the patients with or without other cancers were not significantly different, 55.7+/-10.04 years versus 57.1+/-11.0 years, respectively (p=0.358). History of any cancer in the family and tumor in the lower uterine segment were more frequent among the patients with other cancers (6.0% vs. 1.7%, p=0.095; 12.0% vs. 1.0%, p<0.001; respectively). Six patients had > or =2 other cancers. Ovarian, breast, and colon were the three most common other cancers. After a median follow-up of 57.1 months, 18.3% of patients had died: 30.0% of patients with other cancers and 16.3% of those without other cancers. The corresponding EC deaths were 14.0% and 11.2%. The 5-year overall survival was significantly lower in patients who had other cancers: 79.3% (95% confidence interval [CI], 68.3 to 90.3) vs. 86.0% (95% CI, 81.7 to 90.3) than in those without (p=0.023). However, the corresponding disease-specific survival was not significantly different: 85.1% (95% CI, 75.5 to 94.7) compared with 89.0% (95% CI, 85.1 to 92.9), respectively (p=0.514). CONCLUSION: Thai EC patients had a high incidence of other cancers. Overall survival of EC patients who had other cancers was worse than those without, while disease-specific survival was not significantly different.
Breast Neoplasms/mortality/pathology/therapy
;
Chemotherapy, Adjuvant/methods
;
Colonic Neoplasms/mortality/pathology/therapy
;
Disease-Free Survival
;
Endometrial Neoplasms/mortality/*pathology/therapy
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Middle Aged
;
Neoplasm Recurrence, Local/mortality
;
Neoplasms, Multiple Primary/mortality/*pathology/therapy
;
Neoplasms, Second Primary/mortality/*pathology/therapy
;
Radiotherapy, Adjuvant/methods
;
Tertiary Care Centers/statistics & numerical data
;
Thailand/epidemiology
7.Analysis of the diagnosis and treatment of myoepithelial carcinoma of the parotid gland: report of 17 cases.
Shaoyan LIU ; Email: SAOYANLIU@163.COM. ; Song NI ; Yiming ZHU ; Jian WANG
Chinese Journal of Oncology 2015;37(5):392-394
OBJECTIVEMyoepithelial carcinoma (MC) is a rare malignant neoplasm of the salivary gland. The aim of this study was to analyze the diagnosis, treatment and prognosis of MC of the parotid gland.
METHODSThe clinicopathological data of 17 cases of MC of the parotid gland treated in our hospital from 1999 to 2013 were analyzed retrospectively. Of all the 17 patients, 9 cases received radical surgery only, 5 cases received postoperative radiotherapy, 2 cases received preoperative radiotherapy, and one case received chemotherapy. The survival rate was calculated by Kaplan-Meier analysis.
RESULTSAmong the 17 patients, 11 patients had post-operative recurrence (11/17, 64.7%), Of these 11 cases, 5 cases (45.5%) had recurrence within one year after the first operation. During the follow-up for 12-180 months (median 50 months), six cases died (two patients died of distant metastases and 4 cases died of local recurrence). The overall 1-year, 2-year and 5-year survival rates were 94.1%, 74.2% and 64.9%, and the overall 1-year, 2-year and 5-year recurrence-free survival rates were 70.6%, 48.1% and 40.1%, respectively.
CONCLUSIONSRadical surgery is the main treatment modality for myoepithelial carcinoma of the parotid gland. For the patients with extensive lesions or after palliative surgery, adjuvant radiotherapy or chemotherapy might be helpful. However, its therapeutic efficacy remains to be proved.
Carcinoma ; diagnosis ; therapy ; Combined Modality Therapy ; Humans ; Kaplan-Meier Estimate ; Lymphatic Metastasis ; Myoepithelioma ; diagnosis ; therapy ; Neck Dissection ; Neoplasm Recurrence, Local ; Parotid Gland ; pathology ; Parotid Neoplasms ; diagnosis ; therapy ; Prognosis ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Rate
8.Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors.
Koji MATSUO ; Seiji MABUCHI ; Mika OKAZAWA ; Mahiru KAWANO ; Hiromasa KURODA ; Shoji KAMIURA ; Tadashi KIMURA
Journal of Gynecologic Oncology 2015;26(1):3-11
OBJECTIVE: Presence of high-risk factor in cervical cancer is known to be associated with decreased survival outcomes. However, the significance of multiple high-risk factors in early-stage cervical cancer related to survival outcomes, recurrence patterns, and treatment implications is not well elucidated. METHODS: A retrospective study was conducted for surgically treated cervical cancer patients (stage IA2-IIB, n=540). Surgical-pathological risk factors were examined and tumors expressing > or =1 high-risk factors (nodal metastasis, parametrial involvement, or positive surgical margin) were eligible for analysis (n=177, 32.8%). Survival analysis was performed based on the number of high-risk factors and the type of adjuvant therapy. RESULTS: There were 68 cases (38.4%) expressed multiple high-risk factors (2 high-risk factors: n=58, 32.8%; 3 high-risk factors: n=10, 5.6%). Multiple high-risk factors remained an independent prognosticator for decreased survival outcomes after controlling for age, histology, stage, and treatment type (disease-free survival: hazard ratio [HR], 2.34; p=0.002; overall survival: HR, 2.32; p=0.007). Postoperatively, 101 cases (57.1%) received concurrent chemoradiotherapy (CCRT) and 76 cases (42.9%) received radiotherapy (RT) alone. CCRT was beneficial in single high-risk factor cases: HRs for CCRT over RT alone for cumulative risk of locoregional and distant recurrence, 0.27 (p=0.022) and 0.27 (p=0.005), respectively. However, tumor expressing multiple high-risk factors completely offset the benefit of CCRT over RT alone for the risk of distant recurrence: HR for locoregional and distant recurrence, 0.31 (p=0.071) and 0.99 (p=0.980), respectively. CONCLUSION: Special consideration for the significance of multiple high-risk factors merits further investigation in the management of surgically treated early-stage cervical cancer.
Adult
;
Chemoradiotherapy, Adjuvant
;
Female
;
Humans
;
Hysterectomy/*methods
;
Lymphatic Metastasis
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Neoplasm Staging
;
Radiotherapy, Adjuvant
;
Retrospective Studies
;
Risk Factors
;
Survival Analysis
;
Uterine Cervical Neoplasms/pathology/*surgery
9.Analysis of the effectiveness of radiotherapy in postoperative residual tumors in patients with thyroid papillary carcinoma.
Yuehuang WU ; Junlin YI ; Dehong LUO ; Hongying YANG ; Dezhi LI ; Qingzhuang LIANG
Chinese Journal of Oncology 2015;37(10):776-779
OBJECTIVEThe aim of this study was to assess the impact of radiotherapy on patients with postoperative residual or recurrent papillary thyroid cancer (PTC).
METHODSWe retrospectively reviewed the medical records of 34 patients with PTC, who underwent surgery and radiotherapy in other hospitals, and treated at the Department of Head and Neck Surgery at Cancer Institute & Hospital CAMS from January 2011 to January 2014. Among the 34 cases, 22 were in stage I, 5 in stage II and 7 in stage IVa. The 34 patients received 1.5 times of surgery before radiotherapy in average. All the cases received radiotherapy (mean, 56 Gy; range, 50-70 Gy). The patients were re-operated in our hospital, and the specimens were examined by pathology. The pre- and post-radiotherapy images (CT and B-ultrasound) were compared, and the changes of tumor volume were examined. The objective effect of treatment on the tumor residual focus was evaluated using RECIST, and analyzed by t-test (SPSS 17.0).
RESULTSAll the re-resected lesions after radiotherapy were proved by pathology to be papillary thyroid cancer (PTC) or metastatic PTC in cervical lymph nodes. Among the 34 patients, 22 cases showed mild or moderate cell degeneration and the other 12 cases showed no obvious degeneration. The largest tumor diameter was 27.18 mm before radiotherapy and 27.76 mm after radiotherapy, with a non-significant difference between them (t=-1.618, P>0.05). Among the 34 patients, only 3 patients received reoperation, all other 31 cases had complete resection, and no severe complications were observed except recurrent laryngeal nerve injury in one case.
CONCLUSIONSRadiotherapy has few therapeutic benefit to PTC patients after surgery with residual tumor or local recurrence. It should be used in the PTC patients, in which the tumor invasion involves important organ tissues and is difficult for a single operation to achieve safe resection margin, or in patients who can't bear a surgery because of severe coronary heart disease or others.
Carcinoma ; pathology ; radiotherapy ; surgery ; Carcinoma, Papillary ; Chronic Disease ; Humans ; Lymph Nodes ; Lymphatic Metastasis ; Neck ; Neck Dissection ; Neoplasm Recurrence, Local ; radiotherapy ; Neoplasm, Residual ; Postoperative Period ; Radiotherapy Dosage ; Reoperation ; Retrospective Studies ; Thyroid Neoplasms ; pathology ; radiotherapy ; surgery ; Thyroidectomy ; Tumor Burden
10.Radical prostatectomy and radiation therapy for high-risk prostate cancer: An update.
Jun-hao LEI ; Yong-ji CHEN ; Liang-ren LIU ; Qiang WEI
National Journal of Andrology 2015;21(7):663-666
Recently, the D'Amico classification system is widely used for the risk stratification of prostate cancer (PCa) , although no consensus has been reached for the definition of high-risk PCa. This system defines high-risk PCa as a prostate-specific antigen (PSA) level > 20 ng/ml, a Gleason score of 8-10, or a clinical stage ≥ T2c. Because high-risk PCa is prone to recurrence and metastasis after treatment, a proper initial therapy plays a crucial role. Currently, radical prostatectomy and radiation therapy are considered to be two most important options for the initial treatment of high-risk PCa although it remains controversial which is better.
Humans
;
Male
;
Neoplasm Grading
;
Neoplasm Recurrence, Local
;
Prostate-Specific Antigen
;
blood
;
Prostatectomy
;
methods
;
Prostatic Neoplasms
;
blood
;
pathology
;
radiotherapy
;
surgery
;
Risk

Result Analysis
Print
Save
E-mail